Answers are grounded in this paper and cite their sources.
This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management.
No takes yet. Share an insight, caveat, or question.
Sanjay Kalra (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: